Abstract
Delta-like ligand 3 (DLL3) is overexpressed in most small cell lung cancer (SCLC). Tarlatamab (AMG 757), a half-life extended bispecific T cell engager (HLE BiTE®) molecule, binds DLL3 and CD3 leading to T cell-mediated tumor lysis. Interim phase 1 dose exploration data in SCLC (NCT03319940) show preliminary evidence for tarlatamab efficacy with an acceptable safety profile. Here we report for the first time safety, response, and survival for the combined dose exploration and expansion cohorts.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call